Dr (Lt Col) Pawan Kumar Gupta, is President – Medical & Regulatory Affairs, Stempeutics Research, Bangalore since October 2008, which is the first stem cell company in India focusing on clinical development of major unmet medical needs using allogeneic bone marrow derived Mesenchymal Stromal Cells.

Dr Pawan is a Hematologist & Medical Scientist and has worked in Armed Forces in India for 24 years. He has worked in Stem Cell Institute, University of Minnesota and trained in the field of stem cells. He was the former Dean of Manipal Institute of Regenerative Medicine, Bangalore. Under his leadership the product stempeucel® has progressed from pre-clinical to clinical trials and has been granted manufacturing and marketing approval for three indications in India.

He has more than 100 publications and is the Asia Regional Vice President of International Society of Cell & Gene Therapy.  

Keichiro Mihara, MD, PhD, is a Professor at the International Center for Cell and Gene Therapy and the Department of Cellular Immunotherapies for Cancer at Fujita Health University. He earned his MD from Tottori University and his PhD from Hiroshima University, followed by postdoctoral training at the National Cancer Center Japan and St. Jude Children’s Research Hospital in the United States.

Dr. Mihara previously served as Assistant and later Associate Professor in the Department of Hematology and Oncology at Hiroshima University, where his work centered on hematologic malignancies and cellular immunotherapy. His research spans cancer immunology, translational cell therapy, and hematopoietic disease.

He is an active member of multiple academic societies, including the Japanese Society of Hematology—where he serves as councilor—the American Society of Hematology, and societies focused on oncology, transplantation, cellular therapy, and immunotherapy for hematological disorders.

Koji Tamada, MD, PhD, is President and CEO of Noile-Immune Biotech Inc., Director of the Research Institute for Cell Design Medical Science at Yamaguchi University, and Professor and Chairman of Immunology at the Yamaguchi University Graduate School of Medicine. He also serves as an Adjunct Professor at the Institute of Medical Science, University of Tokyo.

Dr. Tamada completed his medical training and PhD at Kyushu University, followed by advanced research appointments in the United States at the Mayo Clinic, Johns Hopkins University School of Medicine, and the University of Maryland’s Greenebaum Cancer Center. His work has been central to advancing cancer immunology and next-generation cell therapy platforms.

A recognized leader in the field, he holds key roles in several professional societies, including Vice President of both the Japanese Association of Cancer Immunology and the Japan Research Association for Immunotherapeutics. He also serves on the Board of Directors of the Japan Society of Biological Therapy and is a Councillor of the Japanese Cancer Association. Dr. Tamada contributes to scientific publishing as Associate Editor for Cancer Immunology, Immunotherapy and Cancer Science.

Yasushi Tanaka, PhD, is the President of TEIJIN REGENET Co., Ltd., where he oversees the company’s strategic direction and growth in regenerative medicine. Dr. Tanaka has built a broad leadership career across the diagnostics and biomanufacturing sectors, holding roles that span commercial, operational, and executive management.

He previously served as Senior Vice President of Sekisui Diagnostics UK, General Manager of CDMO Business at Sekisui Medical Co., Ltd., and Sales & Marketing Manager at CustomBiotech, Roche Diagnostics. His work has focused on advancing diagnostic technologies, scaling CDMO capabilities, and guiding innovative healthcare businesses through global markets.

Dr. Tanaka assumed the presidency of TEIJIN REGENET in 2023, where he continues to drive the development and commercialization of advanced regenerative medicine solutions.